The regulatory cliff: moving from research-grade to GMP-compliant product
Reading time: 7 minutes
A research-grade reagent that works reliably in a laboratory is not a product you can sell into a clinical manufacturing facility. The transition from one to the other is not an upgrade. It is, in most respects, starting over.
This article examines the regulatory transition that ancillary TechBio companies must navigate when their products touch clinical cell therapy workflows. The Pillar 1 article on GMP and Quality by Design described the regulatory framework in detail. This article focuses on what the transition means in practice for the technology company, and where it most commonly goes wrong. The final article in this Pillar 2 series addresses the broader question of product-market fit that underlies many of these regulatory missteps.
What changes
Good Manufacturing Practice (GMP) governs the manufacture of medicinal products. When a cell therapy enters clinical development, every material, instrument, and process that contacts the cells becomes subject to GMP requirements or must be demonstrated to be fit for purpose in that context. For the ancillary technology company, this means your product is assessed not on whether it works in a research setting but on whether it works within the constraints of a regulated manufacturing environment [1].
The differences are pervasive. Raw materials must be traceable to their source, with certificates of analysis for every lot. Manufacturing specifications must be defined, documented, and validated against acceptance criteria. Changes to specifications, even minor ones, trigger change control procedures. Equipment must be qualified. Software must be validated. The facility in which your product is used must meet defined environmental standards. Documentation must demonstrate that every step was performed as specified, and every deviation must be investigated and assessed for its effect on product quality [1,2].
None of this is optional. A pharma company evaluating your product for use in their clinical manufacturing pipeline will assess not just its technical performance but its regulatory readiness: the quality of your documentation, the traceability of your supply chain, the validation status of your manufacturing process, and the robustness of your change control procedures.
Where companies get caught
Several patterns recur among TechBio companies that encounter the regulatory cliff.
Designing for the bench, not the cleanroom. Many ancillary products are developed in research laboratories using research-grade materials and manual, operator-dependent processes. The product is optimised for scientific performance in the hands of a skilled user. When a clinical customer evaluates it, they find that the materials are not GMP-grade, the manufacturing process is not documented to the level required for regulatory submission, and the product specifications are not formally validated. Redesigning the product for GMP compatibility is not a packaging exercise. It typically requires reformulating with traceable, GMP-grade raw materials, re-optimising the process with those materials, validating the manufacturing process under controlled conditions, and generating a documentation package that demonstrates all of this. The cost and time involved regularly inevitably exceed what the company anticipated.
Deferring regulatory engagement. A common strategy is to develop the product for the research market first, achieve commercial traction, and address regulatory requirements later when clinical customers demand it. The problem is that design decisions made early, material choices, process parameters, supply chain arrangements, can be difficult or impossible to change later without fundamentally altering the product. A culture substrate developed with a research-grade extracellular matrix protein may not be reproducible with a GMP-grade equivalent. A coating process validated in a manual workflow may not transfer to the closed, automated system that manufacturing requires.
Underestimating supply chain requirements. GMP requires that every incoming material meets defined specifications and that the supply chain is audited and controlled. For the ancillary technology company, this means your raw material suppliers must themselves be able to provide the documentation, lot traceability, and consistency that your customers' regulators expect. If your product depends on a single-source research-grade chemical that the supplier manufactures without quality management controls, your clinical pathway is put at risk regardless of how well your product performs.
Treating validation as a one-time event. Process validation in GMP is not a test you pass once. It is an ongoing obligation to demonstrate that your manufacturing process remains under control. This requires continuous monitoring, trend analysis, and a quality management system that detects and responds to drift. Companies that treat validation as a project rather than a system find themselves unprepared when their process, their raw materials, or their customer requirements change.
The specific case of ancillary materials
For products classified as ancillary materials, those that contact the cells during manufacture but are not themselves part of the final therapeutic product, the regulatory requirements are real but sometimes misunderstood. Media, scaffolds, growth factors, enzymes, and coatings all fall into this category.
Regulators expect manufacturers to demonstrate that ancillary materials are suitable for their intended use, that they do not introduce contaminants or alter the safety profile of the final product, and that they are consistently manufactured to defined specifications. The European Medicines Agency and the FDA both expect risk-based qualification of ancillary materials, with the stringency of requirements proportional to the risk the material poses to the final product [1,3].
For the ancillary TechBio company, this creates a graduated pathway. Not every product needs to meet full pharmaceutical GMP from day one. But every product that aspires to clinical application needs a clear understanding of where it sits on the regulatory spectrum and a development plan that moves it toward the required level of qualification. Conversations with regulatory affairs professionals early in product development, rather than after the first clinical customer requests GMP documentation, can save years and significant expense.
From our own experience
Roslin Cells' trajectory illustrates what the regulatory transition involves in practice. Established in 2005, the company spent its first years developing and validating the processes, facilities, and quality systems needed to manufacture human embryonic stem cell lines under GMP conditions. This involved designing and building Scotland's first GMP-grade clean room facilities, developing protocols with GMP-compatible materials, establishing quality management and documentation systems, and securing the regulatory approvals needed to derive and bank clinical-grade cell lines [4].
The subsequent standardisation of iPSC banking for the European Bank for Induced Stem Cells (EBiSC) extended this further, establishing quality-assured processes for the generation, characterisation, and distribution of iPSC lines across multiple partner sites [5]. At every stage, the gap between what worked in research and what was acceptable for regulated manufacture was larger than expected, and closing it required sustained investment in process understanding, documentation, and quality infrastructure.
What this means for TechBio founders
The regulatory cliff is not a cliff because the requirements are unreasonable. It is a cliff because companies reach its edge unprepared. The requirements are published, predictable, and well understood by people who work in regulated manufacturing. What makes them difficult for TechBio startups is that they are fundamentally different from the incentives and practices of the research environment where most products originate.
The reproducibility and scale-up articles in this series described failure modes that the regulatory transition amplifies. A product that is inconsistent between batches cannot pass process validation. A product that loses performance at manufacturing scale cannot meet its specifications. A product whose quality depends on characterisation methods that are not validated for GMP use cannot demonstrate that it meets its Critical Quality Attributes.
The practical recommendation is the same one that applies across this entire series: start earlier than you think. Engage with regulatory affairs expertise during product development. Choose materials with a path to GMP grade. Document your process as you develop it, not afterwards. Build a quality management system before you need one. The companies that treat regulatory readiness as a design constraint rather than a compliance exercise are the ones that make the transition without having to start over. But regulatory readiness is only part of the equation. A product that is GMP-compliant but addresses a need no one has, or solves a problem the market has already moved past, is still a commercial failure. The next and final article in this series examines the broader question of product-market fit in stem cell TechBio.
References
[1] EudraLex Volume 4, Annex 2A: Manufacture of advanced therapy medicinal products for human use. European Commission. 2017.
[2] ICH Q8(R2): Pharmaceutical Development. International Council for Harmonisation. 2009.
[3] Abou-El-Enein M, Romhild A, Kaiser D, et al. Good Manufacturing Practices (GMP) manufacturing of advanced therapy medicinal products: a novel tailored model for optimizing performance and estimating costs. Cytotherapy. 2013;15(3):362-383. DOI: 10.1016/j.jcyt.2012.09.006
[4] De Sousa PA, Downie JM, Tye BJ, Bruce K, Dand P, Dhanjal S, Serhal P, Harper J, Turner M, Bateman M. Development and production of good manufacturing practice grade human embryonic stem cell lines as source material for clinical application. Stem Cell Res. 2016;17(2):379-390. DOI: 10.1016/j.scr.2016.08.011
[5] Steeg R, Mueller SC, Mah N, et al. EBiSC best practice: how to ensure optimal generation, qualification and distribution of iPSC lines. Stem Cell Reports. 2021;16(8):1853-1867. DOI: 10.1016/j.stemcr.2021.07.009
About StemCells.Help
StemCells.Help is an advisory consultancy that aids innovation and real-world impact of life science applications built on developmental and stem cell biology. Founded by Dr Paul De Sousa, it draws on over four decades of experience spanning early embryo development, animal cloning, pluripotent stem cell manufacturing, and technology commercialisation. If you build tools for these domains or work in an emerging application where the biology is the enabling technology, StemCells.Help can provide experienced scientific counsel to ground your decisions. To discuss your needs, talk to Paul.
ORCID: 0000-0003-0745-2504
Web: stemcells.help
